This live, virtual case presentation is intended for AdvancedDegree Candidates (ADCs) - PhDs, MDs, JDs and postdocs. Learn more about the work that we do at BCG!

RSVP FOR THIS EVENT USING THIS LINK. DO NOT RSVP VIA HANDSHAKE:

RSVP FOR THIS EVENT USING THIS LINK. DO NOT RSVP VIA HANDSHAKE: https://talent.bcg.com/Events?folderId=10033123

Measuring the value of a precision oncology drug

Pharmaceutical companies areincreasingly tying drug prices to value. Traditional frameworks that measure the value of a therapy take a narrow approach of measuring the improvement in duration and quality of life vs the change in cost relative to an existing standard of care. While these approaches adequately capture the value of many drugs, they have a number of shortcomings. For example, they often underweight the value of therapies that modestly extend the life of terminal patients, they don’t consider the context for different stakeholders, and they ignore additional sources of value such as spillover effects and the societal benefit of treating rare diseases. These factors are especially relevant for precision therapies that treat terminal oncology. Here at BCG, we have partnered with leading experts to develop a more holistic approach to understanding the overall economic value of a therapy. Colin Shopp, a Consultant from our Chicago office, will lead this virtual session and walk through his specific experience on a BCG client case, where he, alongside a team of BCG consultants, developed a tailored approach to measuring the value of a promising new precision oncology drug.